Media coverage about Globus Medical (NYSE:GMED) has trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Globus Medical earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 45.6256614576257 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several equities research analysts recently issued reports on the company. BTIG Research set a $42.00 price target on Globus Medical and gave the stock a “buy” rating in a report on Monday. Gabelli reiterated a “buy” rating on shares of Globus Medical in a report on Tuesday, November 14th. BidaskClub upgraded Globus Medical from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Zacks Investment Research upgraded Globus Medical from a “sell” rating to a “hold” rating in a report on Friday, November 10th. Finally, ValuEngine upgraded Globus Medical from a “hold” rating to a “buy” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $35.00.
Shares of Globus Medical (GMED) traded down $0.24 during trading hours on Tuesday, reaching $36.35. The company’s stock had a trading volume of 759,000 shares, compared to its average volume of 683,908. The company has a market cap of $3,520.00, a P/E ratio of 29.27, a PEG ratio of 2.85 and a beta of 0.54. Globus Medical has a 52-week low of $20.81 and a 52-week high of $38.04.
In other news, insider A Brett Murphy sold 51,449 shares of the stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $35.00, for a total transaction of $1,800,715.00. Following the completion of the transaction, the insider now owns 49,768 shares in the company, valued at approximately $1,741,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.21% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Globus Medical (GMED) Earns Media Impact Score of 0.24” was reported by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/11/21/globus-medical-gmed-earns-media-impact-score-of-0-24.html.
About Globus Medical
Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.
Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.